entertainment -WSS

entertainment

author：explore 2025-09-27 10:01:15 - browse：25

The New York Stock Exchange (NYSE) — Spencer Platt/Getty Images

Biohaven Pharmaceuticals said Wednesday that a new type of experimental medicine reduced levels of a disease-causing immune molecule by up to 37% in an early-stage study of human volunteers — a result that the company called “positive” as a proof of concept but that also fell short of investor expectations.

The drug, called BHV-1300, belongs to a new class of antibody medicines that shuttle harmful proteins to the liver so they can be removed from the body. BHV-1300 is specifically designed to reduce levels of an autoantibody called IgG that is implicated in rheumatoid arthritis, myasthenia gravis, and other autoimmune disorders.

In its Phase 1 study, Biohaven tested four escalating doses of BHV-1300 in healthy volunteers, showing a reduction in levels of IgG of 5%, 15%, 30%, and 37%, respectively, the company said. The reductions in IgG levels, which occurred relatively quickly in just four to five days, did not cause significant, adverse changes in liver enzyme levels, Biohaven added — an important safety check given the mechanism of the drug.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： Readout Newsletter: Bluebird, CVS, Contineum

WSS

Virtual Event: March of the Biosimilars

Nurses recount patients attacks

New warning issued for rebooking air travel after delays, cancellations

How dance can help health care workers heal from trauma

Physicians and social media: If you see something, say something?

Gilgo Beach murders: What questions remain following Rex Heuermann's arrest?

leisure time

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Novavax promises a turnaround & Lilly roils the obesity market

Ebola public health emergency is over, WHO declares

Peter Hotez and the public health issue of online harassment

Argenx readies a blockbuster opportunity with drug for autoimmune disease

Anesthesiologist group: stop taking Ozempic before surgery

Couple fighting to bring baby home from Mexico are finally reunited

As demand for Covid shots wanes, Moderna seeks its next success

Plane’s emergency slide plummets from sky, hits Chicago home

How to save PrEP access — and even expand it

Plane’s emergency slide plummets from sky, hits Chicago home

focus

SCOTUS questions limit to govt efforts to fight misinformation

STAT's 2023 biotech VC rankings: ARCH Venture Partners tops list

U.K. researchers warn about biases in medical devices, algorithms

India sets sights on home

Trump got a 'target letter.' What is one and what does it mean?

Virtual Event: March of the Biosimilars

hotspot

focus

entertainment

explore